Interview: Chris Garabedian
Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Navigating the New Prescriber’s Path
Cross-Channel Marketing in a Complex Digital World
The New Detail Man’s Journey